Nissan Chemical Industries Limited

Taisho Pharmaceutical Co., Ltd.

Shigetada Sasako

Nagaaki Sato

Hajime Asanuma

Hirofumi Ota

Shoichi Kuroda

Tomomichi Chonan

Takumi Okada

Yudai Imai

Keiko Fusegi

Takanori Kawaguchi

Seishi Ishiyama

Shin Itoh

Masahiro Bohno

Takaaki Ishii

Toshio Nakamura

Toshihito Kumagai

Taketoshi Okubo

Shigeru Tokita

Yoshinori Sekiguchi

Takanori Shimizu

Keishi Hayashi

Kumi Abe

Xiang-Min Sun

Yuri Amada

Noriko Saito

Tomoko Ishizaka

Takayuki Nagatsuka

Souichi Monma

Rui Jibiki

Kengo Watatani

Marie Mizutani

This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior GK-activating effect and is useful as a pharmaceutical. 

2-pyridone compound

A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1],the ring represented by A represents a benzene ring or a pyridine ring,X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, andW represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)},a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

2-pyridone compounds

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MCreceptor antagonistic effect.

Aminopyrrolidine compound

Growing community of inventors

Funabashi, Japan

Shigetada Sasako